Tag - eisai

 
Menu
Search
 
May 02, 2024
 

Today's print edition

Home Delivery
Subscribe for more access

EISAI

Japan Times
BUSINESS / Companies
Jul 6, 2022
Eisai says Alzheimer’s drug will get priority review in U.S.
Under the accelerated approval pathway, drugs can be approved based on their ability to remove amyloid, a hallmark of the disease, from the brain.
Japan Times
BUSINESS
Apr 9, 2022
Japan's Eisai still seeking accelerated U.S. review of Alzheimer's drug
The firm said it plans to seek a quick approval even after the Medicare health plan decided to limit coverage of medicines approved in that manner.
Japan Times
WORLD / Science & Health
Jan 12, 2022
Biogen stung as U.S. limits coverage of Alzheimer’s therapy
Private insurers in the U.S. have mostly declined to cover Aduhelm, saying they need more proof of its efficacy and that benefits outweigh risks like brain swelling.
Japan Times
BUSINESS / Companies
Jul 13, 2021
Eisai pushes second Alzheimer's drug despite call to probe U.S. approval of first
The U.S. Food and Drug Administration's June approval of Aduhelm caused resignations among a panel of independent experts who said the therapy was ineffective.
Japan Times
WORLD / Science & Health / ANALYSIS
Jun 11, 2021
U.S. FDA faces mounting criticism over Alzheimer's drug approval
The drug was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows progression of the disease.
Japan Times
BUSINESS
Jun 9, 2021
Eisai sees potential of new Alzheimer's drug but costs remain concern
The approval by the U.S. Food and Drug Administration of the drug Aduhelm raised hopes, but patients can expect to be charged $56,000 a year.
Japan Times
JAPAN / Science & Health
Jun 8, 2021
Changing the game for Alzheimer's treatment, U.S. approves Eisai and Biogen's drug
The approval appears to signal a fundamental shift in the way the FDA thinks about Alzheimer's disease, which could have lasting ramifications for other drugs in the pipeline.
Japan Times
JAPAN / Science & Health
Jul 1, 2020
Eisai to start clinical trial of experimental drug for COVID-19
Japanese pharmaceutical firm Eisai Co. is set to start clinical trials in the United States of its experimental drug eritoran in the battle against coronavirus, with results potentially available by the year-end, the company said Wednesday.
Japan Times
BUSINESS / Companies
Feb 2, 2020
Japanese firms take Brexit in stride but worry over British prospects for trade talks with EU
Japanese companies in Britain are taking the British exit from the European Union in stride, but some are wary that if Britain-EU trade talks falter, prospects for business in Europe will become uncertain.
Japan Times
BUSINESS
Dec 6, 2019
Biogen builds case for its Alzheimer's drug, but skeptics say more data needed
Biogen Inc. laid out more data Thursday on its experimental Alzheimer's drug, raising no major safety alarms but also offering little compelling evidence that the drug, once declared a failure, actually works.
Japan Times
BUSINESS
Oct 27, 2019
Prolonged Brexit uncertainty frustrating Japanese companies
Japanese manufacturers are growing frustrated yet again over another delay in Britain's withdrawal from the European Union, as the prolonged confusion is raising concerns over disruptions to their businesses and supply chains.
Japan Times
BUSINESS
Oct 23, 2019
Biogen and Eisai revive plans for Alzheimer's drug aducanumab, but prospects still shaky
Biogen Inc. revived plans on Tuesday to seek U.S. approval for the Alzheimer's treatment aducanumab and said data from more patients in two discontinued studies showed the drug reduced the decline of patients.
BUSINESS / Companies
Mar 8, 2018
Japan's Eisai agrees with U.S.-based Merck on potential $5.76 billion cancer drugs deal
Eisai Co. and U.S.-based Merck & Co. said Thursday they have agreed to jointly develop cancer drugs for global sales, with the Japanese pharmaceutical firm potentially receiving up to $5.76 billion if it proves a success.
Japan Times
JAPAN
Jul 12, 2017
Pill-popping is a business worth watching for Japan's drugmakers
To eke out growth in one of the developed world's most sluggish pharmaceutical markets, Japanese drugmakers are turning to the pill-popping behavior of their customers.
WORLD / Science & Health
Mar 25, 2015
Alzheimer's debate revived as Biogen's drug trial advances
Just days after Biogen Inc. revealed promising early data from an experimental Alzheimer's treatment, new research from the Mayo Clinic may revive a long-running debate over whether the drug industry is focusing on the right target in developing therapies to treat the disease.
'So hot you can't breathe': Extreme heat hits the Philippines
A pedestrian cools himself with a folding hand fan as he waits for a ride along a road in Manila on Wednesday, as extreme heat hit the Philippines.
Did Japan intervene to prop up the yen? Analysts think it did.
A man walks past an electronic board displaying the exchange rate for the yen against the U.S. dollar (right) in Tokyo on Tuesday.
Town to block view of Mount Fuji in response to overtourism
The town government of Fujikawaguchiko, Yamanashi Prefecture, decided to set up a 2.5-meter-high screen to prevent tourists from taking pictures of Mount Fuji looming behind a convenience store.
A peek inside the brains of ‘super-agers’
For a little more than a decade, scientists have been studying a subset of people they call "super-agers.” These individuals are age 80 and older, but they have the memory ability of a person 20 to 30 years younger.
Yellow sand allergy: A health issue made worse by climate change
A screenshot of the Meteorological Agency's satellite image of clouds and yellow sand (in pink) on Sunday.
Yellow sand allergy: A health issue made worse by climate change
A screenshot of the Meteorological Agency's satellite image of clouds and yellow sand (in pink) on Sunday.
Climate change, chalky grains and the risks for Japan’s rice farmers
A farmer plants seedlings in Satsumasendai, Kagoshima Prefecture. Japan’s self sufficiency rate for rice is nearly 100%, compared with 38% for food overall, on a calorie basis.
Japan wants you to spend more with ‘luxury tourism’
Performers play a traditional drum unique to Wajima, Ishikawa Prefecture, in the prefectural capital of Kanazawa on March 16 to mark the extension of the Hokuriku Shinkansen line to Tsuruga Station in Fukui Prefecture.
Theaster Gates’ ambitious ‘Afro-Mingei’ brings Black Chicago to Tokyo
Theaster Gates' “A Heavenly Chord” lines up church pews before seven speakers and a Hammond B3 organ, a type of electric organ prevalent in Black American churches.
Casa del Cibo: A thriving jewel born from Tohoku’s harsh past
When chef Ryohei Ikemi moved to Hachinohe, Aomori Prefecture, and opened Casa del Cibo in 2011, it was the first proper Italian restaurant in the city.

Podcast

From easily navigable train stations to the helpfulness of its municipal staff, Tokyo has earned high praise for its commitment to accessibility for disabled travelers.
[Rebroadcast] Japan is doing better on accessibility than you may think

Longform

When trying to trace your lineage in Japan, the "koseki" is the most important form of document you'll encounter.
Climbing the branches of a Japanese family tree
By Alex K.T. Martin

SUSTAINABLE JAPAN

Leading Japan’s sustainability from Tokyo
Leading Japan’s sustainability from Tokyo

SPECIAL SUPPLEMENTS note

Read more

SUPPLEMENTS BINDER